COPD Pharmacology: GOLD 2026 Inhalers, Exacerbations and Emerging Treatments

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information. Overview Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow obstruction. Confirm diagnosis with post-bronchodilator spirometry showing FEV1/FVC below 0.70 in the appropriate clinical context. Pharmacotherapy reduces symptoms and exacerbations but must accompany smoking…

Read Full News

Asthma Drugs: GINA 2026 ICS-Formoterol, Biologics and Safe Treatment

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information. Overview Asthma involves variable respiratory symptoms and variable expiratory airflow limitation. Treatment goals are symptom control and prevention of severe attacks, loss of lung function and medication harms. GINA 2026 emphasizes objective confirmation of the diagnosis, inhaler training…

Read Full News

Bronchodilators: Beta-2 Agonists, Muscarinic Antagonists and Clinical Safety

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information. Overview Bronchodilators relax bronchial smooth muscle and improve airflow in asthma and COPD. They relieve obstruction but do not universally control airway inflammation: this distinction is especially important in asthma, where inhaled corticosteroid (ICS)-containing therapy is needed to…

Read Full News

Serotonin Receptor Agonists and Antagonists: Classification, Uses and Safety

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information. Introduction and receptor classification Serotonin (5-hydroxytryptamine, 5-HT) signals through multiple receptor families. Most are G-protein-coupled receptors; 5-HT3 is a ligand-gated cation channel. Pharmacologic effects depend on receptor subtype and tissue: 5-HT1 receptors generally couple to Gi/o, 5-HT2 to…

Read Full News

Prostaglandins and Eicosanoids: Biosynthesis, Receptors and Therapeutic Drugs

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information. Overview Eicosanoids are short-lived lipid mediators made from polyunsaturated fatty acids, classically arachidonic acid. They include prostaglandins, prostacyclin, thromboxanes, leukotrienes and lipoxins, with important roles in inflammation, vascular tone, platelet function, reproduction, renal perfusion and airway biology [1]….

Read Full News

Antihistamines: H1 Receptors, 2026 Urticaria Treatment and Drug Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Antihistamines are used principally for allergic rhinitis, urticaria, allergic conjunctivitis and selected symptomatic conditions. Most allergy medicines are H1-receptor inverse agonists, not simple competitive antagonists. H2-receptor blockers such as famotidine suppress gastric acid and are not interchangeable…

Read Full News

Gout Pharmacology: Allopurinol, Colchicine, Urate Targets and Flare Management

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Gout is an inflammatory arthritis caused by monosodium urate crystal deposition in joints and tissues. Hyperuricemia arises from urate overproduction or, more commonly, impaired excretion; hyperuricosuria is not required. Treat acute inflammation promptly and use urate-lowering therapy…

Read Full News

Rheumatoid Arthritis DMARDs: Methotrexate, Biologics, JAK Inhibitors and Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview and treatment goals Rheumatoid arthritis (RA) is a systemic autoimmune synovitis that may lead to joint destruction. Early DMARD treatment and a treat-to-target strategy aiming for remission or low disease activity improve outcomes. NSAIDs and corticosteroids can…

Read Full News

NSAIDs: COX Inhibition, Evidence-Based Uses and Gastrointestinal, Renal and Cardiac Risks

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce pain, fever and inflammation chiefly through inhibition of cyclooxygenase-dependent prostaglandin production. Selection depends on indication, duration, cardiovascular risk, prior ulcer/bleeding, kidney function, age, pregnancy and interactions [1,2]. Chemical and pharmacologic classification Salicylates:…

Read Full News

Hematopoietic Growth Factors: 2026 ASCO Guidance, Mechanisms and Safety

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment. Overview Hematopoietic growth factors support production of blood-cell lineages or mobilization of hematopoietic progenitors. Treatment must match the underlying condition: neutropenia, anemia, thrombocytopenia and stem-cell collection have different agents, goals and harms [1,2]. Classes and receptor mechanisms G-CSF:…

Read Full News